Ticker: CERO

CERo Therapeutics Holdings, Inc. (NASDAQ: CERO) - Quick reality check What's happening inside: management is advancing clinical work (CER‑1236 IND active, first AML patient dosed with no dose‑limiting toxicity), but the company is burning cash, relying on frequent financings and facing governance...

CERO Therapeutics Holdings, Inc. (NASDAQ: CERO) has recently released its quarterly report for the period ended March 31, 2025. Here are the key takeaways from the company’s income statement and financial performance: Positive Aspects: **Cash Position:** The company reported cash, cash equivalen...